Neurogene Inc. 8K

Neurogene Inc. used an 8-K to furnish a June 2026 corporate presentation highlighting clinical, regulatory, manufacturing, and commercial progress for its NGN-401 Rett syndrome gene therapy program, including completion of dosing in its registrational Embolden trial and plans toward a future BLA filing and launch readiness.

Neurogene Inc. furnished a June 2026 corporate presentation as an exhibit to its Form 8-K, outlining the advancement of its lead gene therapy candidate NGN-401 for Rett syndrome toward commercialization, including completion of dosing in both its Phase 1/2 trial and the Embolden registrational trial, detailed interim clinical data showing durable multidomain functional improvements with an acceptable safety profile, its regulatory strategy and design of the single-arm Embolden trial intended to support a BLA submission, internal AAV manufacturing and CMC readiness including a planned PPQ campaign starting mid-2026, early commercial planning and payer research for potential premium-priced gene therapy reimbursement, and a cash runway the company expects will fund operations through Embolden topline data, BLA submission, and key pre-launch activities targeted into 2027–2028.

Filing Facts

CIK

1404644

Ticker

-

Form

8K

Source Type

sec

Accession

0001404644-26-000044

Alert Tier

6